The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Abstract
OBJECTIVE: Based on lower rates of acute extrapyramidal side effects associated with second-generation antipsychotics, compared to first-generation antipsychotics, and based on preliminary data, second-generation antipsychotics are expected to cause less tardive dyskinesia than first-generation antipsychotics. This hypothesis was examined in a systematic review of studies involving open or controlled treatment with any second-generation antipsychotic. METHOD: Studies of treatment with second-generation antipsychotics lasting > or =1 year and reporting on new cases of tardive dyskinesia or dyskinesia were systematically reviewed. RESULTS: In 11 studies, 2,769 patients received treatment with risperidone (five studies, N=1,235), olanzapine (two studies, N=610), quetiapine (two studies, N=386), amisulpride (one study, N=331), or ziprasidone (one study, N=207) for a weighted mean and median duration of 263 and 306 days, respectively. Study designs were double blind and randomized (N=3); open-label extensions of double-blind, randomized trials (N=4); and open label (N=4). Of the four trials that had a comparator (all involving adults with schizophrenia spectrum disorders), three used haloperidol (N=408) and one used placebo (N=71). Studied populations included children (N=77), adults (N=1,419), adults and elderly persons (N=794), and exclusively patients age 54 years or older (N=479). The weighted mean annual incidence of tardive dyskinesia for second-generation antipsychotics was 0% in the children, 0.8% (range=0.0%-1.5%) in the adults, 6.8% in the mixed adult and elderly population, and 5.3% (range=0.0%-13.4%) in the patients age 54 years and older, compared to 5.4% (range=4.1%-7.4%) in adults treated with haloperidol. CONCLUSIONS: Results from 11 long-term studies support the idea that second-generation antipsychotics have a reduced risk for tardive dyskinesia, compared to first-generation antipsychotics, although the doses of haloperidol used in the comparator studies were relatively high. More carefully designed studies, ideally lasting beyond 1 year and comparing the effects of different second-generation antipsychotics in patients who have never taken first-generation antipsychotics, are needed to estimate the true risk. It would not appear premature for clinicians to consider these findings in making long-term treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Research Diagnoses for Tardive Dyskinesia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040080014 · Cited by 937
Self-citationLeucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Self-citationLeucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Self-citationCsernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470
Self-citationPurdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Dolder, C. R., Lacro, J. P., Dunn, L. B., & Jeste, D. V. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.103 · Cited by 386
Posttraumatic stress disorder: a model of the longitudinal course and the role of risk factors.
Glazer, W. M. (2000) · PubMed · Cited by 340
Browne, S., Roe, M., Lane, A., Gervin, M., Morris, M., Kinsella, A., Larkin, C., & O'Callaghan, E. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb09835.x · Cited by 332
The Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 302
Self-citationRisk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients
Jeste, D. V. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950210050010 · Cited by 299
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1248 · Cited by 280
JENSEN, P. S., BHATARA, V. S., VITIELLO, B., HOAGWOOD, K., FEIL, M., & BURKE, L. B. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00017 · Cited by 262
Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S. M., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261
Morgenstern, H. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210057007 · Cited by 260
Akathisia Variants and Tardive Dyskinesia
Barnes, T. R. E. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790320042006 · Cited by 255
Beasley, C. M., Dellva, M. A., Tamura, R. N., Morgenstern, H., Glazer, W. M., Ferguson, K., & Tollefson, G. D. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.1.23 · Cited by 241
Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors
Woerner, M. G., Alvir, J. M. J., Saltz, B. L., Lieberman, J. A., & Kane, J. M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1521 · Cited by 230
Self-citationLower Incidence of Tardive Dyskinesia with Risperidone Compared with Haloperidol in Older Patients
Jeste, D. V., Lacro, J. P., Bailey, A., Rockwell, E., Harris, M. J., & Caligiuri, M. P. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01595.x · Cited by 226
Voruganti, L., Cortese, L., Oyewumi, L., Cernovsky, Z., Zirul, S., & Awad, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00154-1 · Cited by 226
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002) · Pediatrics · doi:10.1542/peds.110.3.e34 · Cited by 195
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Loo, H., Poirier-Littre, M.-F., Theron, M., Rein, W., & Fleurot, O. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195
Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006928 · Cited by 189
Prospective Study of Tardive Dyskinesia Incidence in the Elderly
Saltz, B. L. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470170090030 · Cited by 183
Arato, M., O??Connor, R., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178
Purdon, S. E., MALLA, A. K., Labelle, A., & Lit, W. (2001) · PubMed · Cited by 177
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Jeste, D. V., Okamoto, A., Napolitano, J., Kane, J. M., & Martinez, R. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1150 · Cited by 161
Self-citationPharmacologic treatment of schizophrenia
Kane, J. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00059-1 · Cited by 156
Self-citationClozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga, C. A., Thaker, G. K., Moran, M. J., Kakigi, T., & Gao, X. (1994) · PubMed · Cited by 156
A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia
Hirsch, S. R., Kissling, W., Bäuml, J., Power, A., & O'Connor, R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0609 · Cited by 152
Tardive dyskinesia in affective disorders.
Kane, J. M. (1999) · PubMed · Cited by 150
Self-citationGlazer, W. M., Morgenstern, H., & Doucette, J. T. (1993) · PubMed · Cited by 145
Treatment with atypical antipsychotics: new indications and new populations
Glick, I. D., Murray, S. R., Vasudevan, P., Marder, S. R., & Hu, R. J. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00020-6 · Cited by 143
New onset diabetes and atypical antipsychotics
Liebzeit, K. A., Markowitz, J. S., & Caley, C. F. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00127-9 · Cited by 142
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
Colonna, L., Saleem, P., Dondey-Nouvel, L., & Rein, W. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00002 · Cited by 139
Tardive akathisia: An analysis of clinical features and response to open therapeutic trials
Burke, R. E., Kang, U. J., Jankovic, J. J., Miller, L. G., & Fahn, S. (1989) · Movement Disorders · doi:10.1002/mds.870040208 · Cited by 138
Long-term use of quetiapine in elderly patients with psychotic disorders
Tariot, P. N., Salzman, C., Yeung, P. P., Pute, J., & Rak, I. W. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80085-5 · Cited by 128
Jeste, D. V., Lacro, J. P., Palmer, B. W., Rockwell, E., Harris, M. J., & Caligiuri, M. P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.309 · Cited by 122
Risperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders
Vieta, E., Goikolea, J. M., Corbella, B., Benabarre, A., Reinares, M., MartÌnez, G., Fernandez, A., Colom, F., Martínez‐Arán, A., & Carla Torrent for the Group for the Study of Risperidone in Affective Disorders (GSRAD) (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1011 · Cited by 122
Incidence of tardive dyskinesia: five-year data from a prospective study.
Kane, J. M., Woerner, M. G., Weinhold, P., Wegner, J. T., Kinon, B. J., & Borenstein, M. (1984) · PubMed · Cited by 111
Self-citationExtrapyramidal side effects are unacceptable
Kane, J. M. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00109-2 · Cited by 110
Self-citationThe treatment of tardive dyskinesia—a systematic review and meta-analysis
Soares, K., & McGrath, J. J. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00021-3 · Cited by 103
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
Lindström, E., Eriksson, B., Hellgren, A., von Knorring, L., & Eberhard, G. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80105-7 · Cited by 103
Speller, J. C., Barnes, T. R. E., Curson, D. A., Pantelis, C., & Alberts, J. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.6.564 · Cited by 103
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Glazer, W. M. (2000) · PubMed · Cited by 99
Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder
Sanger, T. M., Grundy, S. L., Gibson, P. J., Namjoshi, M. A., Greaney, M. G., & Tohen, M. F. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0410 · Cited by 99
Lemmens, P., Brecher, M., & van Raelen, B. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb00972.x · Cited by 99
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis
Davidson, M., Harvey, P. D., Vervarcke, J., Gagiano, C. A., Hooge, J. D. D., Bray, G., Dose, M., Barak, Y., & Haushofer, M. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200006)15:6<506::aid-gps146>3.0.co;2-v · Cited by 94
Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia
Youssef, H. A., & Waddington, J. L. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02754.x · Cited by 88
Street, J. S., Clark, W. S., Kadam, D. L., Mitan, S. J., Juliar, B. E., Feldman, P. D., & Breier, A. F. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200112)16:1+<::aid-gps569>3.0.co;2-j · Cited by 84
Oosthuizen, P. P., Emsley, R. A., Maritz, J. S., Turner, J., & Keyter, N. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0913 · Cited by 78
A five year follow-up study of tardive dyskinesia.
Chouinard, G., Annable, L., Mercier, P., & Ross‐Chouinard, A. (1986) · PubMed · Cited by 69
Ballesteros, J., Arrillaga, A. G.-P., & Bulbena, A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00011 · Cited by 67
Kumra, S., Jacobsen, L. K., Lenane, M., Smith, A. R., Lee, P. C., Malanga, C. J., Karp, B. I., HAMBURGER, S., & Rapoport, J. L. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199802000-00016 · Cited by 53
Glick, I. D., & Berg, P. H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200203000-00004 · Cited by 51
Bouchard, R.-H., Mérette, C., Pourcher, E., Demers, M., Villeneuve, J., Roy‐Gagnon, M., Gauthier, Y., Cliche, D., Labelle, A., Filteau, M., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00002 · Cited by 47
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Ghaemi, S. N. (2000) · PubMed · Cited by 45
MALLA, A. K., Norman, R. M. G., Scholten, D. J., Zirul, S., & Kotteda, V. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0308 · Cited by 41
Antipsychotic Prescribing Practices
Essock, S. M. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006911 · Cited by 41
Aripiprazole for long-term maintenance treatment of schizophrenia
McQuade, R. D., Kujawa, M. J., Saha, A., Ingenito, G. G., Ali, M. W., Luo, X., Archibald, D., & Carson, W. H. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80498-x · Cited by 33
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics
Bergen, J., Kitchin, R., & Berry, G. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90071-7 · Cited by 32
Long-term safety of risperidone
Brecher, M. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)88092-8 · Cited by 15
A Naturalistic Study of Risperidone Maintenance Treatment of Outpatients With Severe Mental Illness
Megna, J. L., & Dewan, M. J. (1999) · Psychiatric Services · doi:10.1176/ps.50.8.1084 · Cited by 10
Chouinard, G., Lasser, R. A., Bossie, C. A., Zhu, Y., & Gharabawi, G. M. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80443-7 · Cited by 9
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Physical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633
Self-citationNational Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 591
Metadata
- Authors
- Correll, C. U., Leucht, S., & Kane, J. M.
- Venue
- American Journal of Psychiatry
- Published
- 2004-03-01
- Volume
- 161
- Issue
- 3
- Pages
- 414-425
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2171958702
- Cited by
- 709
- References
- 70
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.